CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,…
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung DiseaseMENLO PARK, Calif., Oct. 19, 2022…
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…
Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of careLEXINGTON, Mass., Oct.…
Company presenting technologies for improving patient outcomes in wound careWINNIPEG, Manitoba, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc.…
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and…
Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023LEXINGTON, Mass., Oct. 13, 2022…
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of…
TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022LEXINGTON, Mass., Oct. 12, 2022 (GLOBE…
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022…